Ovarian Cancer | Topics

Phase 2 Trial Reports Positive Outcomes with Treatment Combination for Ovarian Cancer
November 27, 2020

A phase 2 trial found that the combination of pembrolizumab with bevacizumab and oral cyclophosphamide was well tolerated and demonstrated clinical benefit and durable treatment responses in patients with recurrent ovarian cancer.

Study Finds Assisted Reproductive Technology Does Not Lead to Increased Risk of Ovarian Cancer
November 18, 2020

This study found that the increased risk of ovarian cancer in women treated with assisted reproductive technology compared with the general population can likely be explained by nulliparity instead.

EU Approves Olaparib in Combination with Bevacizumab to Treat Advanced Ovarian Cancer
November 06, 2020

AstraZeneca and Merck announced that the combination treatment of olaparib with bevacizumab to treat adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer was approved in the European Union.